Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/2000 First Published: 11/1/1998


1.		Phase III Randomized Study of Intraperitoneal AD 32 Versus Oral Altretamine in Patients with Refractory or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Who Have Failed Platinum and Paclitaxel Chemotherapy (Summary Last Modified 06/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ANTHRA-A9503

Last Modified: 5/31/2007 First Published: 2/1/1999


2.		Phase III Randomized Study of AD 32 Following Transurethral Resection in Patients with Newly Diagnosed or Recurrent Superficial Transitional Cell Carcinoma of the Bladder (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ANTHRA-A9601 NCT00003725

Last Modified: 9/1/1998


3.		Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder Refractory to BCG (Summary Last Modified 09/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ANTHRA-A9301/02 NCI-V95-0695

Last Modified: 9/1/1998


4.		Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder with or without Prior BCG (Summary Last Modified 09/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ANTHRA-A9303 NCI-V95-0696

Last Modified: 7/23/2008 First Published: 12/1/1997


5.		Phase II Study of Intravesical AD 32 in Patients with Recurrent or Refractory Papillary Transitional Cell Carcinoma and/or Carcinoma In Situ of the Bladder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				E-3897 NCT00003129, E3897

Last Modified: 11/1/2002 First Published: 3/1/1999


6.		Phase II Randomized Study of Peri-Operative Intravesical AD 32 Alone or Supplemented with BCG in Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ANTHRA-A9701/ID97-038 MDA-ID-97038, NCT00003759


7.		Phase II Evaluation of Chemotherapy with AD-32 for Patients with Measurable Metastatic Malignant Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified								DFCI-78061

Select All on One Page